Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
Va-Q-tec intensifies activities in China - Implementation of expansion plan in Asia is continued by partnering with Worldwide Logistics - Additional TempChain Service Center to fulfill the growing demand in the region - First business is gained with pharma and non-pharma clients Shanghai/Würzburg, October 8th, 2019. va-Q-tec AG (ISIN DE0006636681 / WKN ...
